Increasing the level of peroxisome proliferator-activated receptor γ coactivator-1α in podocytes results in collapsing glomerulopathy

Szu-Yuan Li,1,2 Jihwan Park,1 Chengxiang Qiu,1 Seung Hyeok Han,3 Matthew B. Palmer,4 Zoltan Arany,5 and Katalin Susztak1

1Renal-Electrolyte and Hypertension Division of Department of Medicine, and Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. 2Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. 4Department of Pathology and Laboratory Medicine, and 5Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

Introduction

Podocytes are highly specialized epithelial cells with a large cell body and elaborate foot processes that surround the glomerular capillaries. Interdigitation of foot processes between adjacent podocytes form the filtration slit, functioning as the final layer of the filtration barrier impeding the passage of macromolecules into the urine. Podocytes are terminally differentiated and have exited the cell cycle. Following injury, podocytes are unable to replicate; therefore, most glomerular diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease (DKD) are associated with podocyte loss (1, 2). Decline in glomerular podocyte density leads to scar formation, causing a decrease in glomerular filtration (3, 4).

Unlike other glomerular diseases, collapsing glomerulopathy (CGN) presents with a distinct histological injury pattern. CGN is characterized by podocyte dedifferentiation, proliferation, and subsequent collapse of the glomerular tuft. Clinically, this injury pattern is associated with a rapid loss of renal function and poor therapeutic response. The pathogenesis of CGN is not well understood. It is best described in the context of HIV infection, but mitochondrial gene mutations and different toxins can also result in this injury pattern (5, 6).

Although constituting only 0.5% of body mass, kidneys consume 10% of the oxygen by the human body. Mitochondrial dysfunction has increasingly been recognized in patients and animal models of chronic kidney disease (CKD). Mutations in CoQ10 biosynthetic genes, such as COQ6, COQ2, and prenyl...
diphosphosphate synthase subunit 2 (PDSS2) have been shown to cause glomerulosclerosis due to mitochondrial dysfunction. Indeed, CoQ10 supplementation ameliorated proteinuria and renal disease in a child with nephrotic syndrome caused by mitochondrial mutation, indicating the critical role of mitochondrial dysfunction in glomerular disease (7–11). Metabolomic studies performed in urine samples suggest a potential acquired mitochondrial defect in patients with DKD (12).

The peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α, encoded by the gene PPARC1A) is a transcriptional coactivator that interacts with other transcriptional factors to regulate mitochondrial biogenesis. Decreased PGC1α expression, mitochondrial loss, and defective mitochondrial function have been described and thought to contribute to various metabolic diseases including heart failure, diabetes, and Parkinson disease (13). Previous studies proposed that Tug1, AMPK, and KLF6 regulate podocyte health and glomerulosclerosis by altering PGC1α expression (14). PGC1α loss was proposed to be the key contributor of mitochondrial dysfunction in renal epithelial cells including podocytes. Transgenic expression of PGC1α in tubule cells can protect mice from development of acute kidney disease and CKD (15).

This study aimed to directly address the role of PGC1α in podocytes using in vivo and in vitro systems. We found that while PGC1α enhances mitochondrial biogenesis and respiratory capacity, excessive PGC1α induces podocyte proliferation, leading to CGN.

Results

Decreased PGC1α expression and mitochondrial transcripts in DKD glomeruli. Gene expression changes of micro-dissected human glomerular samples were analyzed via microarrays (16). Healthy kidney samples (n = 14) were compared to samples obtained from patients with DKD (n = 7). We found that PPARC1A transcript level was significantly lower in DKD glomeruli (P = 0.0009) when compared with controls (Figure 1A). Protein expression was examined by immunohistological staining. In glomeruli, we found that PGC1α protein expression was highest in podocyte nuclei. In line with the transcriptional changes, PGC1α protein expression was also lower in DKD samples (Figure 1B). As PGC1α regulates mitochondrial biogenesis and function, next we performed gene set enrichment analysis. We found that the expression of mitochondrial genes was significantly decreased in DKD samples (Figure 1C), suggesting decreased PGC1α transcriptional activity.

Next, we analyzed PGC1α in glomeruli of mouse DKD models. Mouse models represent early DKD stages. In agreement with the human data, we found that the Prargc1a transcript level was lower in glomeruli (P = 0.015) (Figure 1, D and E) of a leptin receptor–mutant db/db model of type 2 diabetes. Similarly, the Prargc1a level was also lower in glomeruli of streptozotocin-induced type 1 diabetic mice (Figure 1, F and I). Taken together, these results show that PGC1α and mitochondrial transcript levels were lower in glomeruli of patients and mouse models with DKD.

TGF-β regulates PGC1α levels in podocytes. Several factors have been proposed to contribute to podocyte dysfunction in DKD, including high glucose, LPS, and dysregulated cytokine levels (TGF-β, TNF-α, VEGF, and VEGF). To explore the role of these potential mediators in regulating PGC1α expression, we cultured podocytes in the presence and absence of these factors. In our experiments, glucose, TNF-α, VEGF, and LPS did not influence PGC1α levels in podocytes. TGF-β, a key profibrotic cytokine, decreased PGC1α expression (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.92930DS1). This is consistent with previously described binding of Smad3 to the PPARC1A enhancer region (15). Increased TGF-β levels observed in DKD samples might play a role in lowering PGC1α expression in DKD glomeruli.

Increasing PGC1α levels in podocytes causes albuminuria and renal failure. Given the decrease in PGC1α expression in DKD, we next examined whether restoring PGC1α levels can be protective. We generated mice with podocyte-specific inducible PGC1α expression by breeding nephrin-rtTA (Nefta) mice (17), which express the rtTA transactivator specifically in podocytes, with tetO-Pargc1a animals (18), in which the Pargc1a gene is under the control of a doxycycline-responsive promoter element. Double-transgenic mice (Nefta-PGC1α) were born at the expected Mendelian frequency and appeared healthy without evidence of renal histological abnormalities or albuminuria. To induce transgene expression, mice were placed on doxycycline-containing food starting at 4 weeks of age (Figure 2A). Single-transgenic littermates served as controls. PGC1α immunostaining confirmed the successful transgene expression in podocytes (Figure 2B). Kidney function...
measurement showed that Nefta-PGC1α mice developed albuminuria as early as 7 days after doxycycline induction (Figure 2C). Serum biochemical analysis indicated significant azotemia evidenced by elevated blood urea nitrogen (BUN) and creatinine levels (Figure 2, D and E). We observed significant heterogeneity in phenotype severity and timing. Transcript analysis of PGC1α by quantitative PCR (qPCR) indicated a strong positive correlation between albuminuria and glomerular PGC1α levels (Figure 2F). We titrated doxycycline chow amount to control PGC1α transgene expression in the Nefta-PGC1α mice, and found that doubling the PGC1α level was not associated with albuminuria during the 16-week observation period.

We also made these animals diabetic via low-dose streptozotocin injection and found that podocyte-specific PGC1α-transgenic mice were not protected from diabetes-induced albuminuria (Supplemental Figure 2).

In summary, podocytes have a very narrow PGC1α tolerance. Mice with podocyte-specific inducible PGC1α expression developed albuminuria and azotemia. The phenotype strongly correlated with transgene expression.

PGC1α increases mitochondrial biogenesis and function. To understand the mechanism of PGC1α-induced podocyte dysfunction, we used an adenoviral system to increase PGC1α levels of immortalized cultured podocytes. When compared with GFP control adenovirus, PGC1α increased the expression of

---

**Figure 1. Glomerular PGC1α expression and mitochondrial transcript abundance in diabetic glomeruli.**

(A) Glomerular PPARGC1A expression in diabetic kidney disease patients and controls. Box-and-whisker plots depict the median (line within box), 2.5–97.5 percentile (whiskers), and first and third quartiles (bottom and top of box) (n = 21). Significance evaluated by unpaired t test. (B) Representative PGC1α immunostaining of human kidneys. Arrows indicate positive PGC1α staining in podocytes of control samples. Scale bars: 10 μm. (C) Gene set enrichment analysis shows that mitochondrial gene transcript abundance is lower in diabetic human glomeruli compared with control samples. (D) Glomerular Ppara expression level in db/db and control mice (n = 10). (E) Representative PGC1α immunostaining of db/db and control mice. (F) Gene set enrichment analysis of mitochondrial gene transcript abundance in glomeruli of db/db and control mice. (G) Glomerular Ppara mRNA expression level in streptozotocin-injected and control mice (n = 17). (H) Representative PGC1α immunostaining in streptozotocin-injected and control mice. (I) Gene set enrichment analysis of mitochondrial gene transcript abundance in glomeruli of streptozotocin-injected and control mice. PGC1α, peroxisome proliferator-activated receptor γ coactivator-1α; DKD, diabetic kidney disease; STZ, streptozotocin.
mitochondrial genes, including *Esrra*, *Ndfua10*, *Atp5a*, *Atp5b*, and *UCP2* (Figure 3A). Next, we examined mitochondrial structure and content by Mitotracker staining. Representative Mitotracker images of control and PGC1α-expressing podocytes are shown on Figure 3B. Overall, we observed that PGC1α significantly increased mitochondrial density (Figure 3C). In addition, we found that mitochondria formed long tubular networks following PGC1α expression when compared with control cells that contained mostly short, oval-shaped mitochondria (Figure 3B). Mitochondria are highly dynamic organelles that constantly undergo fission (fragmentation) and fusion. Next, we analyzed expression of genes that regulate mitochondrial dynamics. Transcript levels of genes that regulate mitochondrial fusion including *Opa1*, *Mfn1*, and *Mfn2* were significantly increased in PGC1α podocytes. Expression of genes that mediate mitochondrial fission, such as *Drp1* and *Fis1*, were not influenced by increased PGC1α levels (Figure 3D); these observations indicate a PGC1α-induced shift of mitochondrial dynamics towards fusion in podocytes.

We then characterized mitochondrial function using the Seahorse Bioscience XF24 Extracellular Flux Analyzer. Control cells and PGC1α-expressing cells had a similar baseline oxygen consumption rate (OCR). The ATP synthesis inhibitor oligomycin decreased OCR to a lesser degree in PGC1α-expressing cells, suggesting a higher rate of proton leak. The maximal respiratory capacity, analyzed by electron transport chain accelerator p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP) administration, on the other hand, was significantly higher in PGC1α podocytes (Figure 3, E and F). We did not observe differences in ATP levels when PGC1α-expressing podocytes were compared with controls (data not shown). Expression of the antioxidant enzyme *Ucp2* was increased (Figure 3A). We did not detect significant differences in ROS levels in PGC1α-expressing podocytes (data not shown).

*PGC1α alters podocyte energy source preference.* Cardiomyocytes and kidney tubular cells are high-energy-demanding cells, and they preferentially use fatty acid as their energy source (15); however, the fuel preference of podocytes has not been clarified. We again used the Seahorse Bioscience XF24 Analyzer to study...
bioenergetics of podocytes cultured in different fuel–containing media. When compared with palmitate and glutamine, glucose resulted in a much higher increase in OCR in response to FCCP (Figure 4A). Consistent with these findings, blockade of glucose utilization by 2-deoxyglucose significantly suppressed ATP production in podocytes (Figure 4B), indicating that cultured podocytes preferentially use glucose as their energy source. To test the net effect of PGC1α on podocyte fuel preference, we first cultured cells in substrate-limiting medium for 24 hours, and then in medium containing either glucose, palmitate, or glutamine. Compared with control podocytes, cells expressing PGC1α had higher expression of glycolytic genes such as Slc2a4, Hk1, and Hk2. In addition, the transcript level of Pdk4 (the enzyme that inhibits pyruvate conversion to acetyl-CoA and promotes cellular utilization of fatty acids) (19) was also significantly higher (Figure 4C). We did not observe a significant increase in glucose-induced OCR when PGC1α-expressing and control cells were compared (Figure 4, D and E). While palmitate did not change the OCR of control podocytes, it significantly increased the OCR in PGC1α-expressing cells, which was sensitive to the carnitine palmitoyltransferase 1 (CPT-1) inhibitor etomoxir (Figure 4, G and H). Consistently, expression of genes involved in fatty acid oxidation such as Acox2, Acox3, Lpl, Acadl, and Acadvl (Figure 4F) were significantly higher in PGC1α-expressing cells. Glutamine did not alter the OCR in control or PGC1α-transfected podocytes (Figure 4, J and K), even though we observed a slight increase in expression of cell membrane amino acid transporter (Slc1a5) and aspartate aminotransferase (Got1 and Got2) (Figure 4I). Taken together, these data indicate that podocytes preferentially use glucose, although PGC1α slightly shifted cells toward fatty acid utilization.
Figure 4. PGC1α alters mitochondrial fuel preference in podocytes. (A) Oxygen consumption rate (OCR) of podocytes measured by Seahorse XF. Podocytes were cultured in various energy substrates (Seahorse XF Base Medium supplemented with glucose, palmitate, or glutamine). OCRs were measured at baseline, following 1 μM oligomycin, 3 μM FCCP, and 1 μM antimycin/rottenone (n = 5 per group). (B) ATP concentration in control and 2-deoxyglucose-treated podocytes (n = 10). Box-and-whisker plots show the median (line within box), upper and lower quartiles (bounds of box), and minimum and maximum values (whiskers). (C) Expression of genes involved in glycolysis in control and PGC1α-expressing podocytes. Glucose transporter 1 (Slc2a1), Slc2a4, hexokinase 1 (Hk1), Hk2, pyruvate kinase isozymes M1/M2 (Pkm), lactate dehydrogenase A (Ldha), and pyruvate dehydrogenase kinase 4 (Pdk4) were evaluated. (D and E) OCR in glucose/UK5099-treated podocytes (n = 20 per group). (F) Expression of genes involved in fatty acid oxidation in control and PGC1α-expressing podocytes. Acyl-CoA oxidase 1 (Acox1), Acox2, Acox3, lipoprotein lipase (Lpl), acyl-CoA dehydrogenase long chain (Acadl), acyl-CoA dehydrogenase very long chain (Acadvl), carnitine palmitoyltransferase I (Cpt1), and Cpt2 were evaluated. (G and H) OCR in palmitate/etomoxir-treated podocytes (n = 20 per group). (I) Expression of amino acid transporter in control and PGC1α-expressing podocytes. Neutral amino acid transporter B (Slc1a5), glutaminase (Gls), glutamate dehydrogenase 1 (Gdh), glutamic-oxaloacetic transaminase 1 (Got1), and Got2 were evaluated. (J and K) OCR in glutamine/BPTES-treated podocytes (n = 20 per group). *P ≤ 0.05, **P ≤ 0.01 by unpaired t test with Bonferroni correction or 1-way ANOVA with post-hoc analysis. ns, not significant; Ade, adenovirus; BPTES, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide; FCCP, p-trifluoromethoxy carbonyl cyanide phenyl hydrzone; PGC1α, peroxisome proliferator-activated receptor γ coactivator-1α.
RNA sequencing analysis indicates that PGC1α induces aberrant mitochondrial assembly and promotes cell cycle re-entry. PGC1α (being a transcriptional coactivator) can activate multiple downstream pathways including HIF, Notch, Wnt, and PDGF (20–23). Many of these pathways have been proposed to mediate the beneficial or deleterious effects of PGC1α in different cell types (24, 25). We have tested the regulation of genes by comparing their expression in control and PGC1α-transfected podocytes. We did not observe significant and consistent differences in transcript levels when these pathways were analyzed (Supplemental Figure 3).

To better understand the mechanism of PGC1α-induced phenotypic changes in podocytes, we performed RNA sequencing analysis of glomeruli isolated from control and Nefta-PGC1α–transgenic animals. Glomerular isolation and sequencing data processing are detailed in the Methods section. Stringent statistical comparison indicated 460 differentially expressed transcripts between control and transgenic mice (Supplemental Table 1). Next, we performed gene set enrichment analysis to identify key dysregulated pathways. Consistent with our cell biological studies, glomeruli of the Nefta-PGC1α mice showed enrichment for genes involved in oxidative phosphorylation (Figure 5A). The RNA sequencing analysis also indicated that mitochondrial assembly might be impaired in PGC1α-transgenic podocytes. The expression level of most electron transport chain subunits was about 2-fold higher in Nefta-PGC1α–transgenic mice compared with controls. On the other hand, transcripts encoded by the mitochondrial genome (mt-Nd1, mt-Nd2, mt-Nd4, mt-Nd 5, and mt-Nd6 in complex I, mt-Cybt in complex III, and mt-Cox1 in complex IV) were not proportionally increased (Figure 5B). Expression of genes involved in DNA replication and cell cycle pathways were higher in PGC1α-transgenic glomeruli (Figure 5, C and D). Transcript levels of genes involved in cell adhesion were decreased in Nefta-PGC1α–transgenic animals (Figure 5E).

*PGC1α induces podocyte proliferation in vitro.* Differences in expression of cell cycle genes, observed by RNA sequencing, prompted us to examine podocyte proliferation. In cultured podocytes, PGC1α transfection increased BrdU incorporation (Figure 6A), indicating increased cell proliferation. Consistently, the
expression of genes associated with cell proliferation, such as c-Myc, Ccne, and Pcna were also increased (Figure 6B). In cultured podocytes, PGC1α also resulted in a reduction in expression of podocyte-specific genes such as Wt1 and Synpo, indicating dedifferentiation (Figure 6C). We found that blocking fatty acid oxidation by etomoxir was not able to attenuate PGC1α-induced proliferation and de-differentiation. Therefore, mitochondrial fuel shift may not be the main cause of PGC1α-induced cell cycle reentry of podocytes (Supplemental Figure 4).

Podocyte-specific PGC1α expression induces collapsing glomerulosclerosis in vivo. Transmission electron microscopic (TEM) examination of the Nefta-PGC1α mice showed numerous giant mitochondria in podocytes. The cristae of these large mitochondria were generally intact. Occasionally, we also observed binuclear podocytes, indicative of podocyte proliferation. Capillary tuft collapse and podocyte hypertrophy were also observed in TEM images (Figure 7, A and B). qPCR analysis of isolated glomeruli confirmed the increase in expression of electron transport chain (Ndufa10, Atp5b) and mitochondrial fusion (Opa1, Mfn1) genes (Figure 7C). Immunohistochemical staining analysis revealed lack of TUNEL-positive (apoptotic), but a decrease in WT1-positive cell numbers in glomerular cells. There was a significant increase in proliferating cell nuclear antigen–positive (PCNA-positive) cells in Nefta-PGC1α mice. PCNA-positive cells were located at the edge of glomeruli, likely indicating podocyte proliferation (Figure 8A). Immunofluorescence staining indicated that PCNA-positive cells were positive for podocyte marker WT1 but negative for parietal cell marker claudin 1 (Figure 8B). Light microscopic analysis, at the time of development of albuminuria, revealed marked structural changes in Nefta-PGC1α glomeruli. Glomeruli showed global and segmental glomerulosclerosis, podocyte hyperplasia, hypertrophy with pseudocrescent formation, and focal podocyte hyaline droplets. Tubules appeared dilated with proteinaceous cast and severe tubule-interstitial fibrosis (Figure 9, A–D). Silver staining of Nefta-PGC1α kidneys showed marked podocyte hypertrophy and hyperplasia, which occupied the entire Bowman’s space. The glomerular tufts were compressed without capillary lumens (Figure 9E). qPCR analysis, at early time points, indicated a decrease in levels of podocyte differentiation markers (Nphs1, Nphs2, and Synpo) and an increase in proliferation gene Ccne level (Figure 9F). PGC1α did not alter VEGF-a mRNA or protein expression in podocytes in vivo (Supplemental Table 1 and Supplemental Figure 5; see complete unedited blots in the supplemental material). Expression of profibrotic genes such as Col1a1, Col3a1, and Fn was increased at later stages (Figure 9G). Overall, the light microscopic and TEM analyses showed strong resemblance to human CGN, which is characterized by podocyte proliferation and dedifferentiation.
**Discussion**

While PGC1α is abundantly expressed in the kidney, the role and regulation of PGC1α are still poorly understood. PGC1α is a main transcriptional regulator of mitochondrial biogenesis and is highly expressed in mitochondria-rich tissues such as liver, muscle, and kidney. The cellular energy demand is a strong regulator of PGC1α expression. In the liver, PGC1α is induced by fasting; in brown adipose tissue, it is induced by cold temperature; and in skeletal muscle and heart, it is induced by exercise (13).

Impaired PGC1α expression and mitochondrial loss in podocytes have been observed in glomerular disease (12). Recently, the role of several upstream regulators of PGC1α has been shown to contribute to DKD development. The lncRNA Tug1 (26) and AMPK (27) have been shown to decrease PGC1α levels and induce DKD development. Overexpression of Sirt1 has been reported to attenuate aldosterone-induced nephropathy in a rodent model by deacetylating PGC1α and increasing its activity (28). Our analysis also indicated that PGC1α levels are decreased in glomeruli of patients and mice with DKD. All these observations support the hypothesis that a reduced level of PGC1α in podocytes contributes to DKD development.

On the other hand, the direct role of reduced PGC1α levels in glomerulosclerosis development has not been demonstrated. Global-PGC1α-knockout mice do not develop glomerulosclerosis and CKD (29). The role of PGC1α has been proposed based on in vivo and in vitro overexpression studies (15). Under these circumstances, PGC1α increased the expression of multiple metabolic genes and mitochondrial function. These observations only support the potential benefit of improving bioenergetics, but not directly PGC1α.

There are several other transcription factors in the kidney whose expression is also reduced in glomerulosclerosis and might have overlapping functions with PGC1α (30–34). For this reason, here we performed studies to directly address the role of PGC1α in podocytes.

Our studies directly analyzed the role of PGC1α in podocytes by cell type-specific gene targeting. We found that podocytes are unable to tolerate increased PGC1α levels. Podocytes show similarities to cardiomyocytes in this context. Although PGC1α expression and mitochondrial biogenesis are decreased in heart failure patients and mice (35), induction of PGC1α in mouse hearts resulted in alterations in mitochondrial
morphology and heart failure (18, 36, 37). In podocytes, the phenotype development was dose dependent and even a modest increase in PGC1α levels resulted in kidney failure. Podocytes therefore seem to be similar to cardiomyocytes, another postmitotic cell type that is highly sensitive to PGC1α levels (37). Another possible explanation, although very unlikely, could be that postmitotic cells such as podocytes and cardiomyocytes are more sensitive to artificial overexpression of any protein, not just PGC1α.

Similar to cancer cells, metabolic reprogramming by PGC1α seems to alter cell fate in podocytes. Increased PGC1α expression resulted in podocyte proliferation and dedifferentiation. Recent studies described a similar role for PGC1α in different cancer types (38, 39). Mitochondria are tailored to meet the metabolic and signaling needs of each cell. The metabolic and morphological diversity of mitochondria in different cell types is a result of mitochondrial composition, such as tissue-specific differences in expression of oxidative phosphorylation enzymes (40). Changes in mitochondrial intrinsic properties can affect cell characteristics; for example, mitochondrial alterations can directly determine stem cell differentiation (41). There is accumulating evidence showing that PGC1α not only activates mitochondrial biogenesis, but also regulates mitochondrial composition and dynamics. For example, skeletal muscle–specific overexpression of PGC1α increases electron transport chain subunit V-α, ANT1, and UCP-2 (42–44), but decreases UCP3 (43), leading to a fast-twitch type II to slow-twitch type 1 fiber conversion (45). These studies suggest that mitochondria do more than passively adjust to the cell’s need; in contrast, mitochondria might be one of the primary drivers of cell plasticity. Our studies are in line with these observations, and suggest that PGC1α regulates cell fate of podocytes and is able to induce proliferation of normally postmitotic cells.

It is also important to highlight the accumulating evidence supporting the role of mitochondrial dysfunction in CGN development. The number of mitochondria per cell is closely regulated within a given cell type (46). However, accumulation of dysmorphic mitochondria in podocytes has been shown in patient samples with CGN, including bisphosphonate-induced CGN (47–50). In mouse models, prenyltransferase-like mitochondrial protein (Pdss2) mutation leads to dysmorphic mitochondrial accumulation in podocytes and CGN development (51, 52). While PGC1α and podocytes are lost in DKD and FSGS, it seems that CGN is characterized by increased mitochondrial number, suggesting that an overactive PGC1α level may be associated with CGN development.

CGN is a rare disease and therefore it is very difficult to collect enough human samples to perform a comprehensive analysis. A dataset including 6 human CGN glomerular samples (53) clearly showed a trend of increased expression of PGC1α and its downstream target genes (Supplemental Figure 6). Our model demonstrated that excessive PGC1α activity in podocytes phenocopies pathological signatures of CGN, including mitochondrial number increase, mitochondrial morphology change, podocyte proliferation, glomerular tuft collapse, and rapid onset of renal failure, suggesting that excessive PGC1α may be involved in the pathological mechanism of CGN. Future studies shall determine how PGC1α alters mito-
In conclusion, the work presented here shows that in diabetic glomeruli, podocyte PGC1α and mitochondrial gene expression is decreased. Podocytes have a narrow PGC1α tolerance and excessive PGC1α alters mitochondrial properties, which induces podocyte proliferation, leading to a CGN-like phenotype.

Figure 9. Nefta-PGC1α mice develop collapsing glomerulosclerosis. (A) Periodic acid–Schiff (PAS) and Masson staining of kidney sections after starting doxycycline-containing food. (B) Quantification of proteinaceous cast (1–4) in control and Nefta-PGC1α mice. (C) Quantification of glomerular sclerosis. (D) Quantification of tubular injury. (E) Representative silver staining of Nefta-PGC1α glomeruli. (F) qPCR analysis of podocyte differentiation markers and cyclin E, 1 week after doxycycline containing food (n = 8–9 per group). Synaptopodin (Synpo), nephrin (Nphs1), podocin (Nphs2), cyclin E (Ccne) were evaluated. Box-and-whisker plots depict the median (line within box), upper and lower quartiles (bounds of box), and minimum and maximum values (whiskers). (G) Transcript levels of genes associated with fibrosis at different time points. Collagen type I α1 chain (Col1a1), collagen type III α1 chain (Col3a1), and fibronectin (Fn) were evaluated. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 by unpaired t test with Bonferroni correction or 1-way ANOVA with post-hoc analysis. ns, not significant; Nefta, nephrin-rtTA; PGC1α, peroxisome proliferator-activated receptor γ coactivator-1α.
Methods

**Glomerular gene expression analysis.** Microarray data from human diabetic nephropathy samples (GSM1146201–1146207) and tumor nephrectomy without CKD/diabetes mellitus (GSM1146215–1146222, 1146229-1146234) were compared (16). Type 2 diabetes db/db mice were compared with their nondiabetic db/m littermates (GSM833993–834002), and low-dose streptozotocin–induced type 1 diabetic DBA mice were compared with nondiabetic littermates (GSM834015–834031) (54). The data were processed using Bioconductor R package and normalized using the RMA method. Gene set enrichment analysis was performed for human (diabetic nephropathy vs. normal part of tumor nephrectomy) and mouse (db/db vs. db/m; streptozotocin vs. control) samples using the default option. Glomeruli were isolated using manual microdissection or Dynabead perfusion and magnetic separation (55) in human and mouse samples, respectively.

**Animals.** Nefta mice carrying the nephrin-rtTA transgene were obtained from Jeffrey Miner (Washington University, St. Louis, Missouri, USA) (17). TetO-Pgc1a–transgenic mice were purchased from The Jackson Laboratory (stock number 012387). Animals were on the FVB background. We crossed male tetO-Pgc1a mice with female Nefta mice. Double-transgenic mice were identified by genomic PCR analysis. Mice were placed on doxycycline-containing chow (Bio Serv S3888) starting at 4 weeks of age. Type 1 diabetes was induced by daily intraperitoneal injections of streptozotocin (Sigma-Aldrich), 50 mg/kg for 5 days, in 6-week-old male mice (56). Only male mice were used in the study.

**Urine albumin and blood biochemical analysis.** Mouse urine albumin concentration was quantified using an ELISA kit (Bethyl Laboratories) and normalized by creatinine concentration (Pointe Scientific). Serum BUN and creatinine were measured by i-STAT blood analyzer (Abbott).

**Podocyte culture.** The conditional immortalized mouse podocyte line was cultured as described previously (57); all experiments were performed 14 days after thermos-shifting. To test the regulator of PGC1α, podocytes were stimulated either with TGF-β (2 ng/ml), high glucose (30 mg/ml), TNF-α (10 ng/ml), or VEGF (10 ng/ml) at different time points. Podocytes were incubated with an adenovirus encoding murine PGC1α or control GFP for 48 hours. Transfection efficiency was confirmed by GFP visualization, qPCR, and by Western blots.

**Mitochondrial density.** Differentiated podocytes cultured in 96-well plates (2 x 10^4 per well) were stained with MitoTracker Red FM (Thermo Fisher Scientific) according to the manufacturer’s instructions, and the mitochondrial density was read by a plate reader at 588/650 nm and presented as relative fluorescence units (RFU).

**Oxygen consumption experiments and ATP assay.** Differentiated podocytes were seeded in an XF 24-well cell culture plate (Seahorse Bioscience) at 2 x 10^4 cells per well and studied in Seahorse XF Base Medium supplemented with 5 mM glucose and 1 mM glutamine. Based on previous reports we used the ATP synthase inhibitor oligomycin (Agilent) (1 μM), uncoupling agent FCCP (Agilent) (3 μM), and complex I inhibitor antimycin/rotenone (Agilent) (1 μM) (58). For fuel preference experiments, cells were cultured in substrate-limited medium (0.5 mM glucose, 1 mM glutamine, 0.5 mM carnitine, 1% FBS) 24 hours before incubating the cells in glucose (10 mM) and mitochondrial pyruvate carrier inhibitor UK5099 (Sigma) (10 μM); palmitate (200 mM) and CTP-1 inhibitor etomoxir (Sigma) (40 μM); glutamine (10 mM) and glutaminase inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (Sigma) (10 μM). The ATP concentration of cultured podocytes was measured using an ATP Fluorometric Assay Kit (BioVision) according to the manufacturer’s protocol.

**qRT-PCR.** Mouse glomeruli were isolated by Dynabead perfusion as described previously (55). RNA was isolated from harvested cells and tissue using the RNeasy Mini Kit (Qiagen). RNA (1 μg) was reverse transcribed using the cDNA Archival Kit (Life Technologies), and qRT-PCR was run in the ViiA 7 System (Life Technologies) instrument using SYBR Green Master Mix and gene-specific primers. The data were normalized and analyzed using the ΔΔCT method. The primers used are listed in Supplemental Table 2.

**RNA sequencing.** Mouse glomerular RNA quality was assessed with the Agilent Bioanalyzer 2100 and only samples with RIN scores above 7 were used for cDNA production. The library was prepared in the DNA Sequencing Core at UT Southwestern Medical Center (Dallas, Texas, USA). RNA (100 ng) was used to isolate poly(A)-purified mRNA using the Illumina TruSeq RNA Preparation Kit. Single-end 50-bp sequencing was performed in an Illumina HiSeq, and the annotated RNA counts (fastq) were calculated by Illumina’s CASAVA 1.8.2. Sequence quality was surveyed with FastQC. Adaptor and
lower-quality bases were trimmed with TrimGalore. Reads were aligned to the Gencode mouse genome (GRCm38) using STAR-2.4.1d. Read counts for each sample were obtained using HTSeq-0.6.1 (htseq-count). DESeq2 was used to test for differential gene expression between control and transgenic groups. Gene set enrichment analysis was used to identify pathways enriched in the differentially expressed gene groups (59).

**Cell proliferation assay.** Differentiated podocytes were cultured in low-serum (0.2% FBS) medium to fully imitate quiescent podocytes in vivo. A BrdU-based cell proliferation assay was performed according to the manufacturer’s instructions (EMD Millipore, catalog 2750).

**Histology, immunohistochemistry, and TEM.** Histological changes of the kidney were examined by periodic acid–Schiff and Masson staining, and then quantified by a pathologist. Kidney sections were immunostained with primary antibodies against PGC1α (ab54481, Abcam), WT-1 (C-19, Santa Cruz), and PCNA (clone PC10, MAB424, EMD Millipore) after heat-induced antigen retrieval by 10 mM sodium citrate buffer (pH 6.0). Immunofluorescence double staining was performed with antibodies against PGC1α, WT-1, and claudin 1 (ab15098, Abcam) in OCT-embedded frozen sections. TUNEL staining of paraffin sections was used for detection of cell death (ApopTag kit, EMD Millipore). For TEM exam, mouse kidney cortex was fixed with 2.5% glutaraldehyde followed by 0.5% osmium tetroxide. Specimens were then series dehydrated and embedded into epoxy resin according to routine procedures. Ultrathin sections were stained with 2% uranyl acetate and 1% lead citrate. Sections were viewed by TEM and digitally recorded using a JEOL 1010 microscope.

**Statistics.** Statistical analyses were performed using GraphPad Prism software. All values are expressed as mean and standard deviation or box-and-whisker plots. A 2-tailed Student’s t test was used to compare 2 groups. Bonferroni correction was applied for multiple comparisons. One-way ANOVA with post-hoc Tukey test was used to compare multiple groups. A P value less than 0.05 was considered statistically significant.

**Study approval.** All experiments in animals were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania, and were performed in accordance with the institutional guidelines.

**Author contribution**
SYL performed in vitro and in vivo experiments. JP and CQ generated and analyzed the microarray and RNAseq data. SHH helped with the mouse experiments. MBP helped with histopathological analysis. ZA generated the adenovirus and provided help and guidance. SYL and KS wrote the manuscript.

**Acknowledgments**
S.Y. Li received research support from Taipei Veterans General Hospital–National Yang-Ming University Excellent Physician Scientists Cultivation Program 104-V-A-003 and Ministry of Science and Technology R.O.C. MOST 104-2314-B-075-042-MY3. Work in the Susztak lab is supported by NIH grants R01 DK076077, DK087635, and DP3 DK108220.

Address correspondence to: Katalin Susztak, Associate Professor of Medicine and Genetics, University of Pennsylvania, Perelman School of Medicine, 415 Curie Boulevard, 415 Clinical Research Building, Philadelphia, Pennsylvania 19104, USA. Phone: 215.898.2009; Email: ksusztak@mail.med.upenn.edu.


46. Robin ED, Wong R. Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell...


